Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice
Open Access

Tecovirimat for monkeypox

Sheliza Halani, Derek Leong and Peter E. Wu
CMAJ November 28, 2022 194 (46) E1573; DOI: https://doi.org/10.1503/cmaj.221210
Sheliza Halani
Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek Leong
Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter E. Wu
Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Tecovirimat can be prescribed off label for treatment of monkeypox (MPXV) infection

Tecovirimat is an antiviral drug with activity against orthopoxviruses.1 It was approved by Health Canada for the treatment of smallpox in November 2021 and approved in other jurisdictions for the treatment of cowpox, MPXV and smallpox.2 Studies involving animals infected with smallpox showed improved survival, clinical symptoms and viral levels with tecovirimat treatment.1,3 Evidence of efficacy against MPXV derives from animal studies; human experience is limited to safety studies and case reports.3,4

Treatment should be prioritized for patients with severe disease

In a review of 528 infections across 16 countries from April to June 2022, 13% of patients with MPXV were admitted to hospital for presentations that included severe anorectal pain, myocarditis, superimposed soft tissue infection or acute kidney injury.2,4 Encephalitis or hemorrhagic disease were other severe complications.2

Supplies are limited and access requires provincial application

Health care providers can request access to tecovirimat based on clinical judgment and patient consent.2 Local resources and provincial processes to obtain tecovirimat are similar across Canada and provide helpful guidance to providers.2 Reporting of outcomes to Health Canada is mandated upon treatment completion.2

The treatment duration is 14 days

Tecovirimat dosing is 200 mg (for patients 13–25 kg), 400 mg (for patients 25–40 kg) and 600 mg (for patients ≥ 40 kg) orally twice daily.2 Tecovirimat should be prescribed with high-fat meals (25 g of fat) to increase its absorption by 40%–50%.5

Tecovirimat is generally well tolerated

There were no notable safety concerns and only mild adverse events reported in a placebo-controlled safety trial involving 449 adult volunteers (90 received placebo, 359 received tecovirimat).3 Common adverse effects include headache, nausea and gastrointestinal symptoms.2 The risk of clinically relevant drug interactions is likely low owing to the limited treatment duration and because tecovirimat is only a weak inhibitor of CYP2C8 and CYP2C19, and a weak inducer of CYP3A4.1 In the product monograph, QTc prolongation has been reported.5

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Russo AT,
    2. Grosenbach DW,
    3. Chinsangaram J,
    4. et al
    . An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 2021;19:331–44.
    OpenUrlCrossRef
  2. ↵
    Monkeypox antiviral guidance for health care providers. Toronto: Ontario Ministry of Health; 2022. Available: https://www.toronto.ca/wp-content/uploads/2022/07/8ed0-Monkeypox-Antiviral-Guidance-for-HCPENAODA.pdf (accessed 2022 Aug. 15).
  3. ↵
    1. Grosenbach DW,
    2. Honeychurch K,
    3. Rose EA,
    4. et al
    . Oral tecovirimat for the treatment of smallpox. N Engl J Med 2018; 379:44–53.
    OpenUrlCrossRef
  4. ↵
    1. Thornhill JP,
    2. Barkati S,
    3. Walmsley S,
    4. et al.
    SHARE-net Clinical Group. Monkeypox virus infection in humans across 16 countries: April–June 2022. N Engl J Med 2022;387:679–91.
    OpenUrlPubMed
  5. ↵
    Product monograph including patient medication information: PrTPOXX®. Corvallis (OR): SIGA Technologies, Inc.; 2021. Available: https://pdf.hres.ca/dpd_pm/00063782.PDF (accessed 2022 Aug. 15).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 194 (46)
CMAJ
Vol. 194, Issue 46
28 Nov 2022
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tecovirimat for monkeypox
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tecovirimat for monkeypox
Sheliza Halani, Derek Leong, Peter E. Wu
CMAJ Nov 2022, 194 (46) E1573; DOI: 10.1503/cmaj.221210

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Tecovirimat for monkeypox
Sheliza Halani, Derek Leong, Peter E. Wu
CMAJ Nov 2022, 194 (46) E1573; DOI: 10.1503/cmaj.221210
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Tecovirimat can be prescribed off label for treatment of monkeypox (MPXV) infection
    • Treatment should be prioritized for patients with severe disease
    • Supplies are limited and access requires provincial application
    • The treatment duration is 14 days
    • Tecovirimat is generally well tolerated
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A blistering variant of phlegmasia cerulea dolens from underlying squamous cell lung cancer
  • Parechovirus infections in infants
  • Radiation dermatitis in a patient treated for hepatocarcinoma
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Family medicine, general practice, primary care
    • Infectious diseases
    • Internal medicine
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire